XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Equity - USD ($)
Total
Common stock
Retained earnings
Noncontrolling interest
Equity, common shares outstanding at Dec. 31, 2020   14,988,429    
Equity, balance at Dec. 31, 2020 $ 46,873,394 $ 49,121,523 $ (2,131,013) $ (117,116)
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Net income (loss) attributable to common shareholders (3,507,587)   (3,507,587)  
Net loss at subsidiary attributable to noncontrolling interests (95,212)     (95,212)
Net income (loss) (3,602,799)      
Return of common stock - Methotrexate 0      
Share-based compensation, shares   192,684    
Share-based compensation, amount 741,867 $ 741,867    
Repurchase of common shares, shares   (438,359)    
Repurchase of common shares $ (1,410,484) $ (1,410,484)    
Equity, common shares outstanding at Dec. 31, 2021 14,742,754 14,742,754    
Equity, balance at Dec. 31, 2021 $ 42,601,978 $ 48,452,906 (5,638,600) (212,328)
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Net income (loss) attributable to common shareholders (5,570,241)   (5,570,241)  
Net loss at subsidiary attributable to noncontrolling interests (79,798)     (79,798)
Net income (loss) (5,650,039)      
Return of common stock (in shares)   (180,000)    
Return of common stock - Methotrexate (399,600) $ (399,600)    
Share-based compensation, shares   171,655    
Share-based compensation, amount 447,503 $ 447,503    
Repurchase of common shares, shares   (367,793)    
Repurchase of common shares $ (1,025,836) $ (1,025,836)    
Equity, common shares outstanding at Dec. 31, 2022 14,366,316 14,366,616    
Equity, balance at Dec. 31, 2022 $ 35,974,006 $ 47,474,973 $ (11,208,841) $ (292,126)